A Drug Interaction Study of LY3871801 in Healthy Participants
Status:
Not yet recruiting
Trial end date:
2023-03-17
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine the effect of LY3871801 when administered
orally on the levels of methotrexate (part 1), drug cocktail (warfarin, dextromethorphan, and
midazolam) and repaglinide (part 2) in the blood stream when administered orally in healthy
participants. The information about any adverse effects experienced will be collected and the
tolerability of LY3871801 will also be evaluated. The study may last up to approximately 25
days for each participant.